However, the resistance rate of trastuzumab is 66–88% as a single agent and 20–50% when combined with chemotherapy in HER2+ BC, and trastuzumab resistance is the major cause of treatment failure resulting in relapse or death8,9. This evidence concerns the gene ERBB2 and breast cancer.